Skip to main content

Table 2 Traditional coagulation assessment at different time points

From: Does subcutaneous administration of recombinant human erythropoietin increase thrombotic events in total hip arthroplasty? A prospective thrombelastography analysis

Indexes Time points rHu-EPO group (n = 74) Control group (n = 78) P value
FDP (mg/l) Pre-op
POD1
POD7
3.38 ± 1.16
13.34 ± 9.85
15.09 ± 3.97
3.47 ± 2.01
15.95 ± 14.00
16.16 ± 4.25
0.727
0.189
0.110
D-dimer(ng/ml) Pre-op
POD1
POD7
1.18 ± 0.54
4.08 ± 1.75
4.77 ± 1.70
1.22 ± 0.74
4.47 ± 2.33
5.33 ± 2.42
0.710
0.241
0.105
PT(s) Pre-op
POD1
POD7
11.64 ± 0.74
12.83 ± 1.14
12.24 ± 1.16
11.85 ± 0.95
13.05 ± 0.85
12.54 ± 1.06
0.141
0.163
0.099
APTT(s) Pre-op
POD1
POD7
28.61 ± 3.34
31.80 ± 5.71
28.97 ± 3.41
28.81 ± 3.63
33.30 ± 5.48
30.02 ± 3.50
0.720
0.098
0.063
TT(s) Pre-op
POD1
POD7
16.98 ± 0.93
15.86 ± 1.05
15.55 ± 0.77
17.24 ± 1.29
16.20 ± 1.22
15.79 ± 0.97
0.161
0.069
0.094
FIB(g/l) Pre-op
POD1
POD7
3.52 ± 1.09
3.64 ± 1.01
4.82 ± 1.00
3.31 ± 0.95
3.84 ± 0.84
5.01 ± 1.03
0.204
0.176
0.268
INR Pre-op
POD1
POD7
1.01 ± 0.08
1.13 ± 0.17
1.06 ± 0.10
1.03 ± 0.084
1.15 ± 0.11
1.09 ± 0.09
0.062
0.261
0.066
  1. *P < 0.05, Pre-op pre-operation, POD1 postoperative day 1, POD7 postoperative day 7, FDP fibrin degradation products, PT prothrombin time, APTT activated partial thromboplastin time, TT thrombin time, FIB fibrinogen, INR international normalized ratio